4-IODO-6-PHENYLPYRIMIDINE

生物活性靶点体外研究体内研究 4-IODO-6-PHENYLPYRIMIDINE 试剂级价格

CAS号:41270-96-6
英文名:4-IODO-6-PHENYLPYRIMIDINE
中文名:4-IODO-6-PHENYLPYRIMIDINE
CBNumber:CB1686643
分子式:C10H7IN2
分子量:282.08
MOL File:Mol file

4-IODO-6-PHENYLPYRIMIDINE化学性质

沸点 :380.2±30.0 °C(Predicted)
密度 :1.728±0.06 g/cm3(Predicted)
储存条件 :-20°C
溶解度 :DMSO: soluble10mg/mL (clear solution, warmed)
形态 :powder
酸度系数(pKa) :-0.54±0.17(Predicted)
颜色 :white to beige
InChIKey :ZTCJXHNJVLUUMR-UHFFFAOYSA-N

安全信息

危险品标志 :Xn
危险类别码 :22-37/38-41
安全说明 :26-39
WGK Germany :3

4-IODO-6-PHENYLPYRIMIDINE性质、用途与生产工艺

生物活性 4-IPP (4-Iodo-6-phenylpyrimidine)是 macrophage migration inhibitory factor (MIF) 的不可逆抑制剂，是MIF的特异性自杀底物。4-IPP可以抑制NF-κB配体（RANKL）诱导的破骨细胞的受体激活剂，并在体外增强成骨细胞介导的矿化和骨结节的形成。
靶点
Target Value
MIF
()

体外研究

4-IPP is a specific suicide substrate for MIF that binds covalently and irreversibly to MIF to inhibit its biologic activity.
4-IPP inhibits RANKL-induced p65 phosphorylation and nuclear translocation by preventing the interaction of MIF with thioredoxin-interacting protein-p65 complexes.
4-IPP can inhibit receptor activator of NF-κB ligand (RANKL)-induced osteoclastogenesis and potentiate osteoblast-mediated mineralization and bone nodule formation.
4-IPP (0.5-200μM;24-72 hours) inhibits osteoclastogenesis in a dose-dependent manner.
4-IPP(5-20μM; 5 days) inhibits RANKL-induced osteoclast differentiation and bone resorption .

Cell Cytotoxicity Assay

Cell Line:	BMMs
Concentration:	0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM, 25 μM, 50 μM, 100 μM, 200 μM
Incubation Time:	24 hours, 72 hours
Result:	Inhibited osteoclastogenesis in a dose-dependent manner.

Western Blot Analysis

Cell Line:	BMMs
Concentration:	5 μM,10 μM, 20 μM
Incubation Time:	1 day, 3 days, 5 days
Result:	Inhibited RANKL-induced osteoclast differentiation and bone resorption.

体内研究

4-IPP (1 mg/kg, 5 mg/kg; every 2 days; for 8 weeks) ameliorates the bone loss associated with estrogen deficiency by reducing osteoclastic activities and enhancing osteoblastic bone formation.

Animal Model:	8-weeks-old C57BL/6J male mice
Dosage:	1 mg/kg, 5 mg/kg
Administration:	Intraperitoneal injection; every 2 days; for 8 weeks
Result:	Alleviated OVX-induced osteoporosis.